{"id":"W2947217637","doi":"10.1186/s12885-019-5600-x","title":"Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Research and Development; Bristol-Myers Squibb Canada; MorphoSys; Celgene; Sanofi; Deutsches Krebsforschungszentrum; Bristol-Myers Squibb; Novartis Pharma; Roche; Chugai Pharmaceutical; Amgen","keywords":"Lenalidomide; Medicine; Multiple myeloma; Bortezomib; Maintenance therapy; Clinical endpoint; Internal medicine; Oncology; Dexamethasone; Surgery; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05567003,0.003858044,0.003754609,0.001609413,0.002431842,0.003286717,0.00362434,0.005035858,0.01741701],"category_scores_gemma":[0.03418214,0.002288232,0.002657185,0.001576642,0.004641877,0.00193383,0.001862351,0.007176321,0.006276811],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002324881,"about_ca_system_score_gemma":0.009027627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006436608,"about_ca_topic_score_gemma":0.001606959,"domain_scores_codex":[0.9566342,0.03346688,0.001840906,0.003822041,0.002816853,0.001419003],"domain_scores_gemma":[0.9881002,0.004369211,0.001983772,0.001590074,0.001457303,0.002499533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6778801,0.02539209,0.01506754,0.01642369,0.003570409,0.001461455,0.001599596,0.006324487,0.01171131,0.07113579,0.05407612,0.1153574],"study_design_scores_gemma":[0.6388211,0.0937719,0.01389367,0.003383354,0.00335587,0.0007460954,0.0003961519,0.007669998,0.004032167,0.03143757,0.2021241,0.0003680137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.01906971,0.005095302,0.01538079,0.006312503,0.00420515,0.936169,0.004049249,0.0002579339,0.009460283],"genre_scores_gemma":[0.04779048,0.001172235,0.02490906,0.006237464,0.001007877,0.9155395,0.001009892,0.00003951103,0.002293904],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05567003,"threshold_uncertainty_score":0.2944148,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02388272025755686,"score_gpt":0.3073506523200687,"score_spread":0.2834679320625119,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}